SEATTLE, Dec. 21, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Canntab Therapeutics Ltd. (CSE: PILL) (TBF1.F). The company is an emerging leader in solid oral dosage cannabis formulations, which are designed to make cannabinoid dosing more accurate and reliable. With 13 patents pending in the United States and Canada, the company is developing instant release, extended release, flash melt, and bi-layer tablets available in 2.5mg, 5mg, and 10mg formulations to ease these concerns.
Cannabinoids have the potential to radically transform the pharmaceutical industry. For example, new studies suggest that cannabis legalization could reduce opioid prescriptions by about six to 12 percent. The problem is that medical cannabis is very different from pharmaceutical drugs—it’s hard for physicians to prescribe treatments that lack consistency or may be metabolized differently between patients.
Near-term Revenue Potential
Canntab submitted an application to become a licensed producer under the ACMPR back in October. Once the license is granted, the company will be able to process cannabis products at its current production facility in Markham, Ontario with minimal additional capital expenditures compared to a new purpose-built facility. The application is a step in the right direction, but could take months for Health Canada to review and approve the application.
In the meantime, the company partnered with FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FSE: 0K9) in September to begin manufacturing its tablets. The agreement calls for FSD Pharma to assist Canntab in obtaining a license to sell cannabis and provide space at its Cobourg facility near Toronto. Canntab will in turn provide all of the necessary equipment and provide a royalty on products that are manufactured within the facility.
The company delivered manufacturing equipment to FSD Pharma’s Cobourg plant in September that will enable the production of more than 1.5 million tablets per day. Under the terms of the deal, these products will be sold by both FSD Pharma—where it receives half of all profit from sales through its channels—or through Canntab’s channels—where FSD Pharma will receive 3.5 percent of the selling price.
Building Value with Partners
Canntab’s partnership with FSD Pharma is just one of several partnerships that the company has signed over the past several months.
The company’s other partnerships include:
- Dr. Don Garbuz, MD: The company signed a binding term sheet with Dr. Garbuz, a leading orthopedic surgeon, to conduct a clinical study on his patients using Canntab’s sustained release tablets for pain reduction.
- Emblem Corp.: The company is collaborating with Emblem to formulate its cannabinoid-based product portfolio. Dissolution testing indicated that its extended release tablets deliver over 12 hours.
- Labsco Promedic SA: The company agreed to form a joint venture with Labsco Promedic to distribute its products in Mexico.
The agreements expand the company’s distribution into parts of Latin America and Europe, as well as pave the way for robust clinical data to support its claims to reduce pain and operate over an extended period of time.
Looking Ahead
Canntab Therapeutics Ltd. (CSE: PILL) (TBF1.F) represents a compelling investment opportunity. By providing doctors with a better way to prescribe cannabis, the company’s products could open the door to a much larger addressable patient population. The near-term agreement with FSD Pharma helps get products into the market, while numerous distribution agreements could lead to near-term commercialization opportunities.
For more information, visit the company’s website.
Please follow the link to read the full article:
http://www.cannabisfn.com/canntab-fsd-pharma-make-cannabis-more-palatable-for-doctors/
Disclaimer
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
About CFN Media
For Visitors and Viewers
CFN Media’s Cannabis Financial Network (CannabisFN.com) is the destination for savvy investors and business people profiting from the worldwide cannabis industry. Viewers will see breaking news, exclusive content and original programming involving the people, companies and investments shaping the industry.
For Cannabis Businesses & Companies
CFN Media is a leading agency and financial media network dedicated to the cannabis industry. We help private, pre-public and public cannabis companies in the US and Canada attract capital, investors and media attention.
Our powerful digital media and distribution platform conveys a company’s message and value proposition directly to accredited and retail investors and national media active in the North American cannabis markets.
Since 2013, CFN Media has enabled the world’s preeminent cannabis companies to thrive in the capital and public markets.
Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany
Disclaimer
CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
Frank Lane
206-369-7050
Flane@cannabisfn.com